Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer

Oncology ◽  
2009 ◽  
Vol 76 (2) ◽  
pp. 133-141 ◽  
Author(s):  
José Pérez-Regadera ◽  
Alfonso Sánchez-Muñoz ◽  
Javier De-la-Cruz ◽  
Claudio Ballestín ◽  
David Lora ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Prognostic Impact ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Epidermal Growth

scholarly journals Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (7) ◽  
pp. e0158787 ◽  
Author(s):  
Wei-Jie Tian ◽  
Miao-Ling Huang ◽  
Qing-Feng Qin ◽  
Qing Chen ◽  
Kun Fang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Meta Analysis ◽  
Growth Factor Receptor ◽  
Prognostic Impact ◽  
Epidermal Growth

Epidermal growth factor receptor (EGFR) overexpression in patients with advanced cervical cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16538-e16538 ◽  
Author(s):  
Lokesh Viswanath ◽  
T. Naveen ◽  
P. Siddanna ◽  
P. Chetana ◽  
M. Geethasree ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Advanced Cervical Cancer ◽  
Epidermal Growth

scholarly journals Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer

2011 ◽  
Vol 24 (5) ◽  
pp. 720-728 ◽  
Author(s):  
Marlies Schrevel ◽  
Arko Gorter ◽  
Sandra M Kolkman-Uljee ◽  
J Baptist M Z Trimbos ◽  
Gert Jan Fleuren ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Mechanisms ◽  
Growth Factor Receptor ◽  
Epidermal Growth

Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancer

2007 ◽  
Vol 25 (10) ◽  
pp. 1232-1238 ◽  
Author(s):  
Steven A. Limentani ◽  
Adam M. Brufsky ◽  
John K. Erban ◽  
Mohammed Jahanzeb ◽  
Deborah Lewis
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Febrile Neutropenia ◽  
Neoadjuvant Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Epidermal Growth

Purpose To evaluate the combination of docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2) –overexpressing breast cancer. Patients and Methods Patients with stage IIB or III breast cancer, including inflammatory disease, and HER2 overexpression (determined by fluorescent in situ hybridization) were treated with six cycles of docetaxel 60 mg/m2 and vinorelbine 45 mg/m2 administered every 14 days with granulocyte colony-stimulating factor and quinolone prophylaxis. Trastuzumab was administered as a 4 mg/kg loading dose followed by 2 mg/kg weekly for 12 weeks. The primary efficacy end point was pathologic complete response (pCR) in the breast. Results Of 31 enrolled patients, 68% had T3 or T4 tumors and 90% were clinically node positive. Twelve patients (39%; 95% CI, 21.6% to 55.9%) achieved pCR in the breast and lymph nodes and 14 patients (45%; 95% CI, 27.6% to 62.7%) achieved pCR in the breast alone, and 19 patients (61%; 95% CI, 44.1% to 78.4%) were node negative after neoadjuvant therapy. Clinical response was documented in 29 patients (94%; 95% CI, 78.6% to 99.2%) with 26 complete responses (84%; 95% CI, 70.9% to 96.8%). The most commonly reported grade 3/4 toxicities were neutropenia (97%), febrile neutropenia (22%), anemia (6%), mucositis/stomatitis (6%), constipation (6%), and skin rash (6%). Conclusion With clinical response and pCR rates of 94% and 39%, respectively, docetaxel, vinorelbine, and trastuzumab is a highly active neoadjuvant therapy for HER2-overexpressing locally advanced breast cancer. Although well tolerated overall, significant febrile neutropenia was observed despite prophylactic measures; therefore, evaluating a similar regimen using lower docetaxel and/or vinorelbine doses is warranted.

Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer

Oral Oncology ◽  
2005 ◽  
Vol 41 (3) ◽  
pp. 320-327 ◽  
Author(s):  
Xavier Pivot ◽  
Nicolas Magné ◽  
Emmanuel Guardiola ◽  
Gilles Poissonnet ◽  
Olivier Dassonville ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Prognostic Impact ◽  
Hypopharynx Cancer ◽  
Epidermal Growth

Nuclear Y-box binding protein-1 expression as a prognostic marker and correlation with epidermal growth factor receptor expression in cervical cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5085-5085
Author(s):  
Shin Nishio ◽  
Kimio Ushijima ◽  
Shuji Takemoto ◽  
Yuko Sasajima ◽  
Hitoshi Tsuda ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Her2 Expression ◽  
Stromal Invasion ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Poor Outcomes

5085 Background: Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many reports indicate that YB-1 is highly expressed in tumor cells and is a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer (CC). Clinical trials have shown that EGFR inhibitors are effective against CC (JCO 2011). Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. Methods: Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 CC patients who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival and EGFR (HER1 and HER2) expression were investigated. Results: Nuclear YB-1 expression was observed in 41 (20%) of 204 cases and correlated with stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with both HER1 expression (p=0.0114) and HER2 expression (p=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor outcomes in terms of progression-free survival (p=0.0033) and overall survival (p=0.0003). On multivariate analysis, stromal invasion, parametrial invasion, and nuclear YB-1 expression were independent predictors of survival. Conclusions: Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in CC.

Sign in / Sign up

Export Citation Format

Share Document